1 not yet recruiting, 1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Qian Wenbin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 ) CAR T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Not yet recruiting | Qian Wenbin | 27 | 2025-07-08 | 2025-06-23 |
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL Sintilimab - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Qian Wenbin | 51 | 2020-12-10 | 2020-12-09 |
Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Immunotherapy, Adoptive (1) · sintilimab (1)
China (2)